Investigating the role of HIPK2 in pulmonary arterial hypertension
HIPK2 signaling in Pulmonary Arterial Hypertension
This study is looking at how a protein called HIPK2 affects lung blood pressure in people with pulmonary arterial hypertension (PAH), with the hope of finding new ways to treat this condition and improve patients' health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11096004 on NIH RePORTER |
What this research studies
This research focuses on understanding how HIPK2, a protein involved in cell growth and survival, contributes to pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. The study aims to explore the mechanisms by which HIPK2 influences the proliferation and survival of specific cells in the pulmonary arteries, which are crucial for the disease's progression. By examining the role of HIPK2 in these processes, the research seeks to identify new therapeutic targets that could lead to effective treatments for PAH. Patients may benefit from insights gained that could lead to innovative therapies aimed at reversing the harmful changes in their pulmonary arteries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
Not a fit: Patients with other forms of pulmonary hypertension unrelated to the mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reverse the progression of pulmonary arterial hypertension.
How similar studies have performed: While the specific role of HIPK2 in PAH has not been extensively studied, similar approaches targeting cell signaling pathways have shown promise in other conditions.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Kudryashova, Tatiana V — University of Pittsburgh at Pittsburgh
- Study coordinator: Kudryashova, Tatiana V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.